Indica Labs and Visiopharm Deliver an Integrated Digital Pathology Image Management and Analysis Solution
Albuquerque, NM and Hørsholm, Denmark, April 9, 2025 – Indica Labs and Visiopharm today announce the successful integration of Visiopharm’s Discovery image analysis software into Indica’s collaborative image management platform, HALO Link. The integration will enable laboratories to create a customized digital pathology ecosystem optimized for their unique image analysis and collaboration needs.
“We are excited to deliver this combined solution to our customers in collaboration with Visiopharm,” said Steven Hashagen, CEO of Indica Labs. “The fully integrated solution allows for a more seamless user experience when working between Discovery and HALO Link, enhancing efficiency and freeing users to focus on their next discovery.”
“The integration with HALO Link reflects our firm commitment to remaining platform-agnostic across staining systems, scanners and image management systems”, said Michael Grunkin, CEO of Visiopharm. “Indica Labs has rapidly established itself as a key player in the IMS space, and we are very pleased to offer our joint customers a streamlined experience that brings together Indica’s collaborative platform with Visiopharm’s advanced AI-driven image analysis.”
The integration, available as a paid add-on with HALO Link 4.1, enables viewing of annotations, regions of interest (ROI), image markups, and analysis summary results generated in Discovery within HALO Link. HALO Link preserves the annotation layers and colors from Discovery, displays ROI and labels as interactive markups, streamlining viewing, and organizes analysis summary results in the image’s analysis tab. The integration functions with all image types supported by the platforms, as long as the image exists in both the HALO Link and Discovery databases.
HALO Link is a browser-based hub for pathology that helps research organizations worldwide safely and securely manage, share, and analyze digital slides and data. The platform offers seamless collaboration and limitless data organization with robust search capabilities. HALO Link natively integrates with HALO® and HALO AI, and its powerful API enables integration with LIS | LIMS systems, compatible third-party image analysis platforms, such as Discovery, and other third-party databases.
Visiopharm’s Discovery software enables users to explore complex tissue data intuitively and customize analyses to fit their specific experimental needs. Its advanced exploratory capabilities enhance analysis accuracy in complex tissue samples. The ability to develop custom deep-learning-based segmentation algorithms, which can account for both cellular and nuclear morphology, enables precise quantification of biomarkers.
The HALO Link 4.1 release is currently available. Contact support@indicalab.com to initiate a software upgrade.
About Indica Labs:
Indica Labs is the global leader in AI-powered digital pathology software and services. Our flagship HALO® and HALO AI platform revolutionizes quantitative evaluation of whole slide images. HALO Link provides collaborative image management while HALO AP® and HALO AP Dx deliver enterprise digital pathology for primary diagnosis with regulatory clearances in multiple markets. Through a commitment to open pathology, performance, scalability, and ease-of-use, we help pharma companies, diagnostic labs, hospitals, research organizations, and Indica’s own Cloud and Pharma Services make discoveries and diagnoses that transform patient care and scientific discovery.
For more information, please visit https://stg-indicalabs-staging.kinsta.cloud or contact info@indicalab.com.
About Visiopharm:
Visiopharm is a leading provider of AI-driven precision pathology software for research and diagnostics. In research, it is a technology leader providing tools that help scientists, pathologists, and image analysis experts produce accurate data for all types of tissue-based research. In diagnostics, it is a leader within clinical applications, with no fewer than nine diagnostic algorithms cleared under IVDR for EU and UK customers. These applications provide diagnostic decision support and can be easily activated and integrated into existing lab workflows. Founded in 2002, Visiopharm is privately owned and operates internationally with over 750 customer accounts in more than 40 countries. The company’s headquarters are located in Denmark’s Medicon Valley, with legal entities in Sweden, the UK, Germany, the Netherlands, and the United States, and local representation in France and China.
For more information visit visiopharm.com.
Indica Labs Media Contact:
Adam Smith
Visiopharm Media Contact:
Johanne Louise Brændgaard